Supplemental Consolidating Financial Information (Tables)

6 Months Ended

Jun. 30, 2015

Supplemental Consolidating Financial Information [Abstract]

Schedule Of Consolidating Balance Sheet

CONDENSED CONSOLIDATING BALANCE SHEETS (UNAUDITED)

as of June 30, 2015

(in thousands)

	The Company		21C		Subsidiary Guarantors		Subsidiary Non-Guarantors		Eliminations		Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	8,157	$	7,481	$	24,228	$	22,216	$	—	$	62,082
Restricted cash		—		—		3,050		—		—		3,050
Accounts receivable, net		—		1,166		71,026		90,925		—		163,117
Intercompany receivables		282,022		—		—		—		(282,022)		—
Prepaid expenses		—		126		9,791		1,875		—		11,792
Inventories		—		—		4,093		321		—		4,414
Deferred income taxes		(372)		(7,094)		7,466		146		—		146
Other		—		—		6,719		1,787		—		8,506
Total current assets		289,807		1,679		126,373		117,270		(282,022)		253,107
Equity investments in joint ventures		(533,913)		560,290		176,866		73		(202,065)		1,251
Property and equipment, net		—		—		181,486		78,579		—		260,065
Real estate subject to finance obligation		—		—		11,556		—		—		11,556
Goodwill		—		—		293,140		199,584		—		492,724
Intangible assets, net		—		—		52,478		25,352		—		77,830
Other assets		—		26,409		15,461		8,628		—		50,498
Intercompany note receivable		33,330		8,450		—		—		(41,780)		—
Total assets	$	(210,776)	$	596,828	$	857,360	$	429,486	$	(525,867)	$	1,147,031
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	—	$	1,331	$	42,692	$	16,138	$	—	$	60,161
Intercompany payables		—		172,993		79,065		29,964		(282,022)		—
Accrued expenses		(6)		6,710		66,677		27,727		—		101,108
Income taxes payable		(141)		1,355		(2,127)		4,534		—		3,621
Current portion of long-term debt		—		6,100		17,476		7,314		—		30,890
Current portion of finance obligation		—		—		277		—		—		277
Other current liabilities		2,018		—		5,946		775		—		8,739
Total current liabilities		1,871		188,489		210,006		86,452		(282,022)		204,796
Long-term debt, less current portion		—		957,951		27,467		14,261		—		999,679
Finance obligation, less current portion		—		—		12,197		—		—		12,197
Embedded derivative features of Series A convertible redeemable preferred stock		22,402		—		—		—		—		22,402
Other long-term liabilities		1,065		—		32,859		10,770		—		44,694
Deferred income taxes		(666)		(15,699)		18,857		1,106		—		3,598
Intercompany note payable		—		—		93		41,687		(41,780)		—
Total liabilities		24,672		1,130,741		301,479		154,276		(323,802)		1,287,366
Series A convertible redeemable preferred stock		378,471		—		—		—		—		378,471
Noncontrolling interests—redeemable		—		—		—		—		68,794		68,794
Total 21st Century Oncology Holdings, Inc. shareholder’s (deficit) equity		(613,919)		(533,913)		555,881		275,210		(297,178)		(613,919)
Noncontrolling interests—nonredeemable		—		—		—		—		26,319		26,319
Total (deficit) equity		(613,919)		(533,913)		555,881		275,210		(270,859)		(587,600)
Total liabilities and (deficit) equity	$	(210,776)	$	596,828	$	857,360	$	429,486	$	(525,867)	$	1,147,031

CONDENSED CONSOLIDATING BALANCE SHEETS (UNAUDITED)

as of December 31, 2014

(in thousands)

	The Company		21C		Subsidiary Guarantors		Subsidiary Non-Guarantors		Eliminations		Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	65,541	$	123	$	16,614	$	16,889	$	—	$	99,167
Restricted cash		—		—		4,081		2,970		—		7,051
Accounts receivable, net		—		53		64,885		72,869		—		137,807
Intercompany receivables		221,316		556		98,628		—		(320,500)		—
Prepaid expenses		—		98		7,356		1,274		—		8,728
Inventories		—		—		4,149		377		—		4,526
Deferred income taxes		(372)		(7,094)		7,465		228		—		227
Other		—		—		6,593		864		—		7,457
Total current assets		286,485		(6,264)		209,771		95,471		(320,500)		264,963
Equity investments in joint ventures		(458,028)		566,587		88,959		58		(195,930)		1,646
Property and equipment, net		—		—		197,031		73,726		—		270,757
Real estate subject to finance obligation		—		—		22,552		—		—		22,552
Goodwill		—		—		278,750		190,846		—		469,596
Intangible assets, net		—		—		56,813		24,867		—		81,680
Other assets		—		12,002		15,557		7,971		—		35,530
Intercompany note receivable		35,330		8,450		1,120		—		(44,900)		—
Total assets	$	(136,213)	$	580,775	$	870,553	$	392,939	$	(561,330)	$	1,146,724
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	—	$	670	$	40,691	$	16,274	$	—	$	57,635
Intercompany payables		—		220,123		—		100,377		(320,500)		—
Accrued expenses		—		11,724		48,028		22,857		—		82,609
Income taxes payable		(141)		1,437		(1,956)		2,774		—		2,114
Current portion of long-term debt		—		—		18,195		8,155		—		26,350
Current portion of finance obligation		—		—		433		—		—		433
Other current liabilities		—		—		18,291		1,396		—		19,687
Total current liabilities		(141)		233,954		123,682		151,833		(320,500)		188,828
Long-term debt, less current portion		—		816,386		110,656		13,729		—		940,771
Finance obligation, less current portion		—		—		23,610		—		—		23,610
Embedded derivative features of Series A convertible redeemable preferred stock		15,843		—		—		—		—		15,843
Other long-term liabilities		—		—		27,453		23,626		—		51,079
Deferred income taxes		(665)		(15,699)		19,070		1,774		—		4,480
Intercompany note payable		—		—		—		44,900		(44,900)		—
Total liabilities		15,037		1,034,641		304,471		235,862		(365,400)		1,224,611
Series A convertible redeemable preferred stock		328,926		—		—		—		—		328,926
Noncontrolling interests—redeemable		—		—		—		34,524		15,273		49,797
Total 21st Century Oncology Holdings, Inc. shareholder’s (deficit) equity		(480,176)		(453,866)		566,082		115,929		(228,145)		(480,176)
Noncontrolling interests—nonredeemable		—		—		—		6,624		16,942		23,566
Total (deficit) equity		(480,176)		(453,866)		566,082		122,553		(211,203)		(456,610)
Total liabilities and (deficit) equity	$	(136,213)	$	580,775	$	870,553	$	392,939	$	(561,330)	$	1,146,724

Schedule Of Consolidating Statements Of Operations And Comprehensive Income (Loss)

CONSOLIDATING STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

Three Months Ended June 30, 2015

(in thousands)

	The Company		21C		Subsidiary Guarantors		Subsidiary Non-Guarantors		Eliminations		Consolidated
Revenues:
Net patient service revenue	$	—	$	—	$	140,358	$	123,022	$	—	$	263,380
Management fees		—		—		14,652		559		—		15,211
Other revenue		—		50		5,514		866		—		6,430
(Loss) income from equity investment		(58,748)		(5,271)		5,954		7		58,246		188
Intercompany revenue		658		367		21,053		—		(22,078)		—
Total revenues		(58,090)		(4,854)		187,531		124,454		36,168		285,209
Expenses:
Salaries and benefits		2		—		91,007		56,388		—		147,397
Medical supplies		—		—		16,547		8,227		—		24,774
Facility rent expenses		—		—		11,496		5,426		—		16,922
Other operating expenses		—		—		9,800		6,273		—		16,073
General and administrative expenses		—		549		35,373		7,854		—		43,776
Depreciation and amortization		—		—		17,142		5,100		—		22,242
Provision for doubtful accounts		—		—		2,036		1,717		—		3,753
Interest expense, net		(1)		21,496		2,325		506		—		24,326
Early extinguishment of debt		—		31,076		6,314		—		—		37,390
Electronic health records incentive payment		—		—		(114)		114		—		—
Fair value adjustment of earn-out liability		3,083		—		(110)		(228)		—		2,745
Fair value adjustment of embedded derivative		5,217		—		—		—		—		5,217
Loss on foreign currency transactions		—		—		—		(31)		—		(31)
Intercompany expenses		—		—		—		22,078		(22,078)		—
Total expenses		8,301		53,121		191,816		113,424		(22,078)		344,584
(Loss) income before income taxes		(66,391)		(57,975)		(4,285)		11,030		58,246		(59,375)
Income tax (benefit) expense		—		—		15		3,073		—		3,088
Net (loss) income		(66,391)		(57,975)		(4,300)		7,957		58,246		(62,463)
Net income attributable to noncontrolling interests—redeemable and non-redeemable		—		—		—		952		(3,027)		(2,075)
Net (loss) income attributable to 21st Century Oncology Holdings, Inc. shareholder		(66,391)		(57,975)		(4,300)		8,909		55,219		(64,538)
Unrealized comprehensive (loss) income		—		—		—		(2,062)		—		(2,062)
Comprehensive (loss) income		(66,391)		(57,975)		(4,300)		5,895		58,246		(64,525)
Comprehensive income attributable to noncontrolling interests-redeemable and non-redeemable		—		—		—		—		(1,866)		(1,866)
Comprehensive (loss) income attributable to 21st Century Oncology Holdings, Inc. shareholder	$	(66,391)	$	(57,975)	$	(4,300)	$	5,895	$	56,380	$	(66,391)

CONSOLIDATING STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

Six Months Ended June 30, 2015

(in thousands)

	The Company		21C		Subsidiary Guarantors		Subsidiary Non-Guarantors		Eliminations		Consolidated
Revenues:
Net patient service revenue	$	—	$	—	$	278,822	$	241,315	$	—	$	520,137
Management fees		—		—		30,142		939		—		31,081
Other revenue		—		82		9,416		2,764		—		12,262
(Loss) income from equity investment		(75,506)		(1,554)		7,982		20		69,270		212
Intercompany revenue		1,326		706		40,022		—		(42,054)		—
Total revenues		(74,180)		(766)		366,384		245,038		27,216		563,692
Expenses:
Salaries and benefits		4		—		184,283		110,069		—		294,356
Medical supplies		—		—		34,067		16,998		—		51,065
Facility rent expenses		—		—		22,857		10,940		—		33,797
Other operating expenses		—		—		17,644		13,353		—		30,997
General and administrative expenses		—		1,091		57,012		14,583		—		72,686
Depreciation and amortization		—		—		34,776		10,035		—		44,811
Provision for doubtful accounts		—		—		4,362		3,859		—		8,221
Interest expense, net		(1)		42,573		6,371		1,070		—		50,013
Early extinguishment of debt		—		31,076		6,314		—		—		37,390
Fair value adjustment of earn-out liability		3,083		—		122		—		—		3,205
Fair value adjustment of embedded derivative		6,559		—		—		—		—		6,559
Loss on foreign currency transactions		—		—		—		211		—		211
Intercompany expenses		—		—		—		42,054		(42,054)		—
Total expenses		9,645		74,740		367,808		223,172		(42,054)		633,311
(Loss) income before income taxes		(83,825)		(75,506)		(1,424)		21,866		69,270		(69,619)
Income tax (benefit) expense		—		—		(30)		5,808		—		5,778
Net (loss) income		(83,825)		(75,506)		(1,394)		16,058		69,270		(75,397)
Net income attributable to noncontrolling interests—redeemable and non-redeemable		—		—		—		—		(4,383)		(4,383)
Net (loss) income attributable to 21st Century Oncology Holdings, Inc. shareholder		(83,825)		(75,506)		(1,394)		16,058		64,887		(79,780)
Unrealized comprehensive (loss) income		—		—		—		(4,497)		—		(4,497)
Comprehensive (loss) income		(83,825)		(75,506)		(1,394)		11,561		69,270		(79,894)
Comprehensive income attributable to noncontrolling interests-redeemable and non-redeemable		—		—		—		—		(3,931)		(3,931)
Comprehensive (loss) income attributable to 21st Century Oncology Holdings, Inc. shareholder	$	(83,825)	$	(75,506)	$	(1,394)	$	11,561	$	65,339	$	(83,825)

CONSOLIDATING STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

Three Months Ended June 30, 2014

(in thousands)

	The Company		21C		Subsidiary Guarantors		Subsidiary Non-Guarantors		Eliminations		Consolidated
Revenues:
Net patient service revenue	$	—	$	—	$	133,854	$	112,096	$	—	$	245,950
Management fees		—		—		16,526		330		—		16,856
Other revenue		—		20		2,955		214		—		3,189
(Loss) income from equity investment		(204,012)		(181,789)		2,014		—		383,690		(97)
Intercompany revenue		—		238		23,088		—		(23,326)		—
Total revenues		(204,012)		(181,531)		178,437		112,640		360,364		265,898
Expenses:
Salaries and benefits		35		—		88,555		47,213		—		135,803
Medical supplies		—		—		17,427		7,075		—		24,502
Facility rent expenses		—		—		11,573		5,594		—		17,167
Other operating expenses		—		—		10,227		5,869		—		16,096
General and administrative expenses		12		233		27,636		6,179		—		34,060
Depreciation and amortization		—		—		17,739		4,423		—		22,162
Provision for doubtful accounts		—		—		2,566		862		—		3,428
Interest expense, net		—		22,295		4,216		3,388		—		29,899
Impairment loss		—		—		182,000		—		—		182,000
Equity initial public offering expenses		4,163		—		—		—		—		4,163
Electronic health records incentive payment		—		—		7		(7)		—		—
Loss on sale leaseback transaction		—		—		—		—		—		—
Fair value adjustment of earn-out liability		—		—		204		—		—		204
Loss on foreign currency transactions		—		—		—		79		—		79
Gain on foreign currency derivative contracts		—		—		—		—		—		—
Intercompany expenses		—		—		—		23,326		(23,326)		—
Total expenses		4,210		22,528		362,150		104,001		(23,326)		469,563
(Loss) income before income taxes		(208,222)		(204,059)		(183,713)		8,639		383,690		(203,665)
Income tax (benefit) expense		—		430		(1,632)		2,136		—		934
Net (loss) income		(208,222)		(204,489)		(182,081)		6,503		383,690		(204,599)
Net income attributable to noncontrolling interests—redeemable and non-redeemable		—		—		—		(1,487)		(1,438)		(2,925)
Net (loss) income attributable to 21st Century Oncology Holdings, Inc. shareholder		(208,222)		(204,489)		(182,081)		5,016		382,252		(207,524)
Unrealized comprehensive (loss) income		—		—		—		(750)		—		(750)
Comprehensive (loss) income		(208,222)		(204,489)		(182,081)		5,753		383,690		(205,349)
Comprehensive income attributable to noncontrolling interests-redeemable and non-redeemable		—		—		—		—		(2,873)		(2,873)
Comprehensive (loss) income attributable to 21st Century Oncology Holdings, Inc. shareholder	$	(208,222)	$	(204,489)	$	(182,081)	$	5,753	$	380,817	$	(208,222)

CONSOLIDATING STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

Six Months Ended June 30, 2014

(in thousands)

	The Company		21C		Subsidiary Guarantors		Subsidiary Non-Guarantors		Eliminations		Consolidated
Revenues:
Net patient service revenue	$	—	$	—	$	264,592	$	195,266	$	—	$	459,858
Management fees		—		—		32,845		608		—		33,453
Other revenue		—		41		5,554		524		—		6,119
(Loss) income from equity investment		(243,196)		(199,226)		(6,102)		9		448,380		(135)
Intercompany revenue		—		445		42,293		—		(42,738)		—
Total revenues		(243,196)		(198,740)		339,182		196,407		405,642		499,295
Expenses:
Salaries and benefits		69		—		180,926		80,717		—		261,712
Medical supplies		—		—		32,964		13,272		—		46,236
Facility rent expenses		—		—		23,252		9,410		—		32,662
Other operating expenses		—		—		19,126		11,351		—		30,477
General and administrative expenses		12		364		52,820		10,978		—		64,174
Depreciation and amortization		—		—		35,078		7,806		—		42,884
Provision for doubtful accounts		—		—		5,357		2,367		—		7,724
Interest expense, net		—		44,214		8,051		5,161		—		57,426
Impairment loss		—		—		182,000		—		—		182,000
Equity initial public offering expenses		4,163		—		—		—		—		4,163
Electronic health records incentive payment		—		—		75		(75)		—		—
Loss on sale leaseback transaction		—		—		135		—		—		135
Fair value adjustment of earn-out liability		—		—		403		—		—		403
Loss on foreign currency transactions		—		—		—		107		—		107
Gain on foreign currency derivative contracts		—		(4)		—		—		—		(4)
Intercompany expenses		—		—		—		42,738		(42,738)		—
Total expenses		4,244		44,574		540,187		183,832		(42,738)		730,099
(Loss) income before income taxes		(247,440)		(243,314)		(201,005)		12,575		448,380		(230,804)
Income tax (benefit) expense		—		380		(1,631)		4,291		—		3,040
Net (loss) income		(247,440)		(243,694)		(199,374)		8,284		448,380		(233,844)
Net income attributable to noncontrolling interests—redeemable and non-redeemable		—		—		—		(1,985)		(1,876)		(3,861)
Net (loss) income attributable to 21st Century Oncology Holdings, Inc. shareholder		(247,440)		(243,694)		(199,374)		6,299		446,504		(237,705)
Unrealized comprehensive (loss) income		—		—		—		(10,606)		—		(10,606)
Comprehensive (loss) income		(247,440)		(243,694)		(199,374)		(2,322)		448,380		(244,450)
Comprehensive income attributable to noncontrolling interests-redeemable and non-redeemable		—		—		—		—		(2,990)		(2,990)
Comprehensive (loss) income attributable to 21st Century Oncology Holdings, Inc. shareholder	$	(247,440)	$	(243,694)	$	(199,374)	$	(2,322)	$	445,390	$	(247,440)

Schedule Of Consolidating Statement Of Cash Flows

CONSOLIDATING STATEMENT OF CASH FLOWS (UNAUDITED)

Six Months Ended June 30, 2015

(in thousands)

Cash flows from operating activities	The Company		21C		Subsidiary Guarantors		Subsidiary Non-Guarantors		Eliminations		Consolidated
Net (loss) income	$	(83,825)	$	(75,506)	$	(1,394)	$	16,058	$	69,270	$	(75,397)
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation		—		—		30,441		7,890		—		38,331
Amortization		—		—		4,335		2,145		—		6,480
Deferred rent expense		—		—		188		150		—		338
Deferred income taxes		—		—		(214)		(567)		—		(781)
Stock-based compensation		5		—		—		—		—		5
Provision for doubtful accounts		—		—		4,362		3,859		—		8,221
Gain on the sale of property and equipment		—		—		(248)		5		—		(243)
Early extinguishment of debt		—		31,076		6,314		—		—		37,390
Gain on foreign currency transactions		—		—		—		38		—		38
Fair value adjustment of earn-out liability		3,083		—		122		—		—		3,205
Fair value adjustment of embedded derivative		6,559		—		—		—		—		6,559
Amortization of debt discount		—		746		—		—		—		746
Amortization of loan costs		—		2,630		—		—		—		2,630
Equity interest in net loss (earnings) of joint ventures		75,506		1,554		(7,982)		(20)		(69,270)		(212)
Distribution received from unconsolidated joint ventures		—		—		106		—		—		106
Changes in operating assets and liabilities:
Accounts receivable and other current assets		—		(1,113)		(9,283)		(27,525)		—		(37,921)
Income taxes payable		—		(82)		(171)		1,902		—		1,649
Inventories		—		—		56		68		—		124
Prepaid expenses		—		(28)		(554)		(421)		—		(1,003)
Intercompany payable / receivable		(60,706)		(46,568)		91,504		15,770		—		—
Accounts payable and other current liabilities		—		(194)		1,950		639		—		2,395
Accrued deferred compensation		—		—		492		194		—		686
Accrued expenses / other current liabilities		(6)		(5,014)		18,429		6,281		—		19,690
Net cash provided by (used in) operating activities		(59,384)		(92,499)		138,453		26,466		—		13,036
Cash flows from investing activities
Purchases of property and equipment		—		—		(18,926)		(6,827)		—		(25,753)
Acquisition of medical practices		—		—		(17,661)		(7,950)		—		(25,611)
Restricted cash associated with medical practices		—		—		4,001		—		—		4,001
Proceeds from the sale of property and equipment		—		—		1,081		41		—		1,122
Loans to employees		—		—		153		7		—		160
Intercompany notes to / from affiliates		2,000		—		1,213		(3,213)		—		—
Purchase of noncontrolling interest - non-redeemable		—		—		(1,233)		—		—		(1,233)
Distributions received from joint venture entities		—		196		2,896		—		(3,092)		—
Premiums on life insurance policies		—		—		(475)		(195)		—		(670)
Change in other assets and other liabilities		—		—		(89)		(67)		—		(156)
Net cash (used in) provided by investing activities		2,000		196		(29,040)		(18,204)		(3,092)		(48,140)
Cash flows from financing activities
Proceeds from issuance of debt		—		963,900		382		6,336		—		970,618
Principal repayments of debt		—		(820,050)		(84,290)		(7,377)		—		(911,717)
Repayments of finance obligation		—		—		(136)		—		—		(136)
Proceeds from issuance of noncontrolling interest		—		—		—		3,230		—		3,230
Proceeds from noncontrolling interest holders – redeemable and non-redeemable		—		—		743		—		—		743
Cash distributions to noncontrolling interest holders—redeemable and non-redeemable		—		—		—		—		(2,022)		(2,022)
Payments for contingent considerations		—		—		(12,184)		—		—		(12,184)
Payments of call premium on long term debt		—		(18,563)		(6,314)		—		—		(24,877)
Cash distributions to shareholders		—		—		—		(5,114)		5,114		—
Payments of loan costs		—		(25,626)		—		—		—		(25,626)
Net cash (used in) provided by financing activities		—		99,661		(101,799)		(2,925)		3,092		(1,971)
Effect of exchange rate changes on cash and cash equivalents		—		—		—		(10)		—		(10)
Net (decrease) increase in cash and cash equivalents		(57,384)		7,358		7,614		5,327		—		(37,085)
Cash and cash equivalents, beginning of period		65,541		123		16,614		16,889		—		99,167
Cash and cash equivalents, end of period	$	8,157	$	7,481	$	24,228	$	22,216	$	—	$	62,082

CONSOLIDATING STATEMENT OF CASH FLOWS (UNAUDITED)

Six Months Ended June 30, 2014

(in thousands)

Cash flows from operating activities	The Company		21C		Subsidiary Guarantors		Subsidiary Non-Guarantors		Eliminations		Consolidated
Net (loss) income	$	(247,440)	$	(243,694)	$	(199,374)	$	8,284	$	448,380	$	(233,844)
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation		—		—		30,025		5,250		—		35,275
Amortization		—		—		5,053		2,556		—		7,609
Deferred rent expense		—		—		259		(29)		—		230
Deferred income taxes		—		(49)		—		427		—		378
Stock-based compensation		71		—		—		—		—		71
Provision for doubtful accounts		—		—		5,357		2,367		—		7,724
Loss (gain) on the sale of property and equipment		—		—		84		(25)		—		59
Loss on sale leaseback transaction		—		—		135		—		—		135
Impairment loss		—		—		182,000		—		—		182,000
Equity initial public offering expenses		4,163		—		—		—		—		4,163
Gain on foreign currency transactions		—		—		—		—		—		—
Gain on foreign currency derivative contracts		—		(4)		—		—		—		(4)
Fair value adjustment of earn-out liability		—		—		403		—		—		403
Amortization of debt discount		—		905		55		341		—		1,301
Amortization of loan costs		—		2,927		—		112		—		3,039
Equity interest in net loss (earnings) of joint ventures		243,196		199,226		6,102		(9)		(448,380)		135
Distribution received from unconsolidated joint ventures		—		—		106		—				106
Changes in operating assets and liabilities:
Accounts receivable and other current assets		—		(5)		(6,554)		(20,418)		—		(26,977)
Income taxes payable		644		(1,316)		(715)		738		—		(649)
Inventories		—		—		(609)		170		—		(439)
Prepaid expenses		—		(42)		2,018		1,120		—		3,096
Intercompany payable / receivable		2,659		8,138		(20,467)		9,670		—		—
Accounts payable and other current liabilities		(859)		126		11,585		3,005		—		13,857
Accrued deferred compensation		—		—		438		153		—		591
Accrued expenses / other current liabilities		—		89		10,995		526		—		11,610
Net cash provided by (used in) operating activities		2,434		(33,699)		26,896		14,238		—		9,869
Cash flows from investing activities
Purchases of property and equipment		—		—		(23,295)		(9,852)		—		(33,147)
Acquisition of medical practices		—		—		933		(41,776)		—		(40,843)
Restricted cash associated with medical practices		—		2		(616)		(10,378)		—		(10,992)
Proceeds from the sale of property and equipment		—		—		28		45		—		73
Loans to employees		—		(1)		(424)		15		—		(410)
Intercompany notes to / from affiliates		—		(2,400)		(339)		2,739		—		—
Contribution of capital to joint venture entities		—		(2,370)		(239)		—		1,989		(620)
Distributions received from joint venture entities		—		293		1,314		—		(1,607)		—
Proceeds (payment) of foreign currency derivative contracts		—		26		—		—		—		26
Premiums on life insurance policies		—		—		(297)		(153)		—		(450)
Change in other assets and other liabilities		—		—		95		(496)		—		(401)
Net cash (used in) provided by investing activities		—		(4,450)		(22,840)		(59,856)		382		(86,764)
Cash flows from financing activities
Proceeds from issuance of debt		—		60,400		5,650		63,966		—		130,016
Principal repayments of debt		—		(23,500)		(8,083)		(10,176)		—		(41,759)
Repayments of finance obligation		—		—		(113)		—		—		(113)
Proceeds from issuance of noncontrolling interest		—		1,250		—		—		—		1,250
Proceeds from noncontrolling interest holders – redeemable and non-redeemable		—		—		1,750		468		(1,989)		229
Cash distributions to noncontrolling interest holders—redeemable and non-redeemable		—		—		—		—		(956)		(956)
Cash distributions to shareholders		—		—		—		(2,563)		2,563		—
Payments of costs for equity securities offering		(2,550)		—		—		—		—		(2,550)
Payments of loan costs		—		—		—		(967)				(967)
Net cash (used in) provided by financing activities		(2,550)		38,150		(796)		50,728		(382)		85,150
Effect of exchange rate changes on cash and cash equivalents		—		—		—		(35)		—		(35)
Net (decrease) increase in cash and cash equivalents		(116)		1		3,260		5,075		—		8,220
Cash and cash equivalents, beginning of period		161		122		9,084		8,095		—		17,462
Cash and cash equivalents, end of period	$	45	$	123	$	12,344	$	13,170	$	—	$	25,682